The Economic Times
English EditionEnglish Editionहिन्दीગુજરાતીमराठीবাংলাಕನ್ನಡമലയാളംதமிழ்తెలుగు
| 09 November, 2026, 04:42 AM IST | Today's ePaper
My Watchlist
Search
+
Business News›ranbaxy laboratories
    SEARCHED FOR:

    RANBAXY LABORATORIES

    SC clears forensic audit of Fortis-IHH deal involving erstwhile Religare promoters Singh brothers

    The Supreme Court has cleared the way for a Delhi High Court-appointed forensic auditor to examine transactions involving Fortis Healthcare, Malaysia’s IHH Healthcare and entities linked to former promoters Malvinder and Shivinder Singh. The audit will trace assets linked to the brothers and examine the dilution of their Fortis shareholding.

    Supreme Court backs Delhi HC orders in Daiichi-Fortis dispute, clears way for forensic audit

    The Supreme Court has declined to interfere with Delhi High Court orders in the long-running Daiichi Sankyo-Fortis dispute, allowing a forensic audit to proceed as part of efforts to trace assets linked to enforcement of a 2016 arbitral award against former Fortis promoters. The apex court did not examine the merits.

    Yes Bank moves SC against forensic audit in Fortis share sale issue

    Yes Bank has approached the Supreme Court challenging a recent Delhi High Court directive. The court ordered a forensic audit into the sale of Fortis Healthcare shares. Yes Bank argues it was not a party to the original arbitration proceedings. However, the bank does not oppose auditing Fortis and its former promoters. It will provide relevant transaction information within legal limits.

    'Ranbaxy Laboratories Ltd is a 'SELL' call with a target of Rs 705 and a stop loss of Rs 739.'

    "Ranbaxy Laboratories Ltd is a 'SELL' call with a target of Rs 595 and a stop loss of Rs 634."

    Buy Ranbaxy Laboratories with stop loss of Rs 438 for target of Rs 475.

    The Economic Times
    BrowseCompanies:
    BACK TO TOP